ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
University of Calgary Joins Trial of LSALT Peptide for Complications in Hospitalized COVID-19 Patients
January 12, 2021Arch Biopartners announced the University of Calgary Cumming School of Medicine has joined the Phase II trial of its lead drug LSALT peptide (Metablok), targeting the prevention of acute lung injury, acute kidney injury, and other complications ... -
First Patient Dosed in Trial to Treat Complications in COVID-19
October 22, 2020Arch Biopartners has dosed the first patient in the Phase II trial of its lead drug LSALT peptide, targeting prevention of acute lung injury, acute kidney injury and other complications caused by inflammation in hospitalized patients with moderate to ...
Pharma Sources Insight January 2025
